These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9589245)

  • 1. Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients.
    Nielsen FS; Sato A; Ali S; Tarnow L; Smidt UM; Kastrup J; Parving HH
    Diabetes Care; 1998 May; 21(5):804-9. PubMed ID: 9589245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients.
    Lièvre M; Marre M
    Diabetes Care; 1999 Jan; 22(1):178-9. PubMed ID: 10333928
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
    Mathew J; Sleight P; Lonn E; Johnstone D; Pogue J; Yi Q; Bosch J; Sussex B; Probstfield J; Yusuf S;
    Circulation; 2001 Oct; 104(14):1615-21. PubMed ID: 11581138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial.
    Cağlar N; Dincer I
    Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1359-68. PubMed ID: 22288296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy.
    Nielsen FS; Ali S; Rossing P; Bang LE; Svendsen TL; Gall MA; Smidt UM; Kastrup J; Parving HH
    Diabet Med; 1997 Jul; 14(7):538-46. PubMed ID: 9223391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
    Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
    Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.
    Fogari R; Zoppi A; Mugellini A; Maffioli P; Preti P; Derosa G
    Expert Opin Pharmacother; 2012 Jun; 13(8):1091-9. PubMed ID: 22515416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Remission of left ventricular hypertrophy with ramipril independently of blood pressure changes: the HYCAR study (cardiac hypertrophy and ramipril)].
    Lièvre M; Guéret P; Gayet C; Roudaut R; Delair S; Boissel JP
    Arch Mal Coeur Vaiss; 1995 Feb; 88 Spec No 2():35-42. PubMed ID: 7646310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study.
    Sadowski Z; Szwed H; Kuch-Wocial A; Kubasik A; Januszewicz W; Krupa-Wojciechowska B; Polak G; Stejfa M; Dvorak I; Balazovjech I; Dubai G; Simon K
    J Hypertens Suppl; 1998 Aug; 16(3):S55-62. PubMed ID: 9747912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial.
    Lonn E; Shaikholeslami R; Yi Q; Bosch J; Sullivan B; Tanser P; Magi A; Yusuf S
    J Am Coll Cardiol; 2004 Jun; 43(12):2200-6. PubMed ID: 15193680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.
    Yilmaz R; Altun B; Kahraman S; Ozer N; Akinci D; Turgan C
    Ren Fail; 2010; 32(8):903-12. PubMed ID: 20722555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy.
    Szwejkowski BR; Gandy SJ; Rekhraj S; Houston JG; Lang CC; Morris AD; George J; Struthers AD
    J Am Coll Cardiol; 2013 Dec; 62(24):2284-93. PubMed ID: 23994420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment.
    Rodilla E; Pascual JM; Costa JA; Martin J; Gonzalez C; Redon J
    J Hypertens; 2013 Aug; 31(8):1683-91. PubMed ID: 23835910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy.
    Seeman T; Gilík J; Vondrák K; Simková E; Flögelová H; Hladíková M; Janda J
    Am J Hypertens; 2007 Sep; 20(9):990-6. PubMed ID: 17765141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group.
    Lièvre M; Guéret P; Gayet C; Roudaut R; Haugh MC; Delair S; Boissel JP
    Hypertension; 1995 Jan; 25(1):92-7. PubMed ID: 7843761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients.
    Scaglione R; Argano C; Di Chiara T; Parrinello G; Colomba D; Avellone G; Donatelli M; Corrao S; Licata G
    J Hum Hypertens; 2007 Apr; 21(4):307-15. PubMed ID: 17301824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study.
    Gosse P; Sheridan DJ; Zannad F; Dubourg O; Guéret P; Karpov Y; de Leeuw PW; Palma-Gamiz JL; Pessina A; Motz W; Degaute JP; Chastang C
    J Hypertens; 2000 Oct; 18(10):1465-75. PubMed ID: 11057435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ramipril on left ventricular mass in normotensive hemodialysis patients.
    Yu WC; Lin YP; Lin IF; Chuang SY; Chen CH
    Am J Kidney Dis; 2006 Mar; 47(3):478-84. PubMed ID: 16490627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.